Rimonabant Hydrochloride CAS:158681-13-1

Rimonabant est medicamentum anorecticum anti-obesity producti et venales Sanofi-Aventis .. . Praecipuum eius adituum effectus est deminutio in appetitu. Rimonabant est primus receptator selectivus CB1, qui ubique terrarum usus probandus est.

Rimonabant hydrochloride, novum pondus medicamento, non solum amittere, sed etiam demittere sanguinem pressura, et sanguis sugar cholesterol. And it is also the first drug in a new class of selective canna binoid type 1 receptor antagonists, is showing promise in clinical trials for the treatment of obesity and related metabolic risk factors, in addition to tobacco dependence, when lost significant body weight when treated with rimonabant 20 mg for a year.

1. Treatment of cardiovascular diseases
2. Smoking cessation
3. Hypertension
4. Dyslipidemia
5. Type 2 diabetes and metabolic syndrome